Wellgistics Health, Inc. acquires Tollo Health, LLC for USD 4,000,000,000 (2026)

Deal facts

Buyer: Wellgistics Health, Inc.
Target: Tollo Health, LLC
Deal value: USD 4,000,000,000
Announced: 20 May 2026
Status: Firm intention
Sector: Healthcare
Country: United States
Consideration: shares, cash

Sources

What we know

Wellgistics Health, Inc. has agreed to acquire Tollo Health, LLC in a strategic acquisition valued at USD 4 billion based on enterprise value. The transaction will be settled through a combination of shares and cash. Both entities are headquartered in the United States and operate within the healthcare sector. The deal was announced on 20 May 2026, marking a significant consolidation of capabilities within the industry.

The transaction remains subject to regulatory approval and customary closing conditions before completion. No completion date has been confirmed at this stage. The parties have reached a firm intention agreement regarding the terms of the merger. This acquisition represents a major capital deployment for the buyer in the US market. The deal structure allows for a flexible consideration mix to align with shareholder interests.

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

1 update

20 May 2026Firm intention
Wellgistics Health, Inc. firm intention to acquire Tollo Health, LLC
Item 1.01 Entry into a Material Definitive Agreement. On May 20, 2026, Wellgistics Health, Inc. (the “Company”) entered into a Fully Binding Letter of Intent, dated May 20, 2026 (the “Term Sheet”), with EOS Technology Holdings, Inc. (“EOS”), Scilex Holding Company / Scilex Holdings, Inc. (“SCLX”), Datavault AI, Inc. (“Datavault”), HealthBridge Advisors, LLC (“HBA”), and Fortitude Advisors, LLC (“F
Source

OpinionExit Mode editorial

The announcement that Wellgistics Health, Inc. intends to acquire Tollo Health, LLC for four billion USD marks a significant consolidation within the US healthcare sector. This is not a small tuck-in deal but a strategic acquisition of substantial scale, executed through a mixed consideration of shares and cash. For the SME founder watching from the other side of the Atlantic, the sheer magnitude of this valuation signals that the market is rewarding specific operational capabilities in healthcare logistics and technology. The deal status is currently listed as firm intention, which in US practice often precedes a definitive agreement subject to standard conditions, yet it demonstrates a clear commitment from the buyer to secure this asset.

We see this transaction as a clear indicator that strategic buyers are willing to deploy significant capital to secure market share and operational scale in the healthcare space. The use of a mixed consideration structure is notable, as it aligns the interests of the Tollo Health founders with the future performance of the combined entity while providing immediate liquidity. This approach often reflects a buyer's desire to manage cash flow while ensuring the selling team remains motivated post-close. It also introduces specific commercial mechanics that founders must understand, such as the potential for earn-out contingencies or escrow arrangements that might be attached to the share component. The regulatory context in the US will likely involve scrutiny from the Federal Trade Commission regarding competition thresholds, given the size of the transaction and the sector involved.

Our view is that the SME founder must look beyond the headline number and dissect the deal mechanics to understand what is truly being sold. A four billion USD price tag implies that the target possesses defensible intellectual property or a dominant market position that justifies the premium. However, the reliance on shares means the final value is not fixed at the announcement date but fluctuates with the buyer's stock performance. This creates a direct link between the founder's legacy and the buyer's future execution. The mixed consideration structure also means that tax planning becomes critical, as the treatment of cash versus shares differs significantly under US and UK tax regimes.

The direct takeaway for the founder is to request a detailed breakdown of the proposed consideration split before signing any preliminary terms. Do not accept a verbal assurance on the cash-to-share ratio, as this single variable will determine your immediate liquidity and your long-term exposure to market volatility. Ask your advisors to model the tax implications of each component under both US and UK law this week, ensuring you understand exactly how much of the four billion USD you will actually retain in hand versus what is deferred in equity.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2026 deals More strategic acquisition deals More from Wellgistics Health, Inc.All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

Not statedCompletedHealthcare

Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited

Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…

Buyer: Circle Health Holdings Limited
Target: CHC Healthcare Holdings Limited
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

11 August 2026ClearedHealthcare

Dolby Medical Home Respiratory Care Limited (Vivisol) to acquire Air Liquide Healthcare Limited’s home oxygen services business

Dolby Medical Home Respiratory Care Limited, trading as Vivisol, has agreed to acquire the home oxygen services business of Air Liquide Healthcare Limited in a strategic…

Buyer: Dolby Medical Home Respiratory Care Limited (Vivisol)
Target: Air Liquide Healthcare Limited’s home oxygen services business
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

10 August 2026Firm intentionHealthcare

RSLGH, LLC to acquire RYTHM, Inc.

RSLGH, LLC has agreed to acquire RYTHM, Inc., a healthcare company based in the United States, in a strategic acquisition valued at $109.5 million. The transaction invol…

Buyer: RSLGH, LLC
Target: RYTHM, Inc.
Deal value: USD 109,500,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

5 August 2026CompletedHealthcare

Ensysce Biosciences, Inc. to acquire Cy Biopharma, Inc.

Ensysce Biosciences, Inc. has agreed to acquire Cy Biopharma, Inc. in a strategic acquisition within the healthcare sector. The transaction was announced on 5 August 202…

Buyer: Ensysce Biosciences, Inc.
Target: Cy Biopharma, Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

31 July 2026Firm intentionHealthcare

Profusa, Inc. to acquire G3 Vision Labs Inc.

Profusa, Inc. has agreed to acquire G3 Vision Labs Inc. in a strategic acquisition within the healthcare sector. The transaction involves the exchange of shares as the p…

Buyer: Profusa, Inc.
Target: G3 Vision Labs Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

Buyer history